<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pediatric Renal Masses | Dr. Mikael Petrosyan</title>
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/theme/black.min.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.1/css/all.min.css">
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800;900&family=Playfair+Display:wght@700;800;900&display=swap" rel="stylesheet">
  <style>
    :root {
      --navy: #0a1628;
      --teal: #0ea5e9;
      --emerald: #10b981;
      --amber: #f59e0b;
      --rose: #f43f5e;
      --purple: #8b5cf6;
      --slate: #94a3b8;
      --white: #f8fafc;
    }
    .reveal { font-family: 'Inter', -apple-system, sans-serif; font-size: 28px; color: var(--white); }
    .reveal .slides { text-align: left; }
    .reveal .slides section { padding: 40px 60px; height: 100%; box-sizing: border-box; }
    .reveal h1, .reveal h2, .reveal h3 { font-family: 'Playfair Display', serif; text-transform: none; letter-spacing: -0.02em; color: var(--white); }
    .reveal h1 { font-size: 2.8em; font-weight: 900; line-height: 1.1; }
    .reveal h2 { font-size: 1.7em; font-weight: 800; margin-bottom: 0.5em; }
    .reveal h3 { font-size: 1.2em; font-weight: 700; color: var(--teal); margin-bottom: 0.4em; }
    .reveal p, .reveal li { line-height: 1.6; font-weight: 400; }
    .reveal ul { list-style: none; padding: 0; }
    .reveal ul li { padding: 0.15em 0; padding-left: 1.5em; position: relative; font-size: 0.9em; }
    .reveal ul li::before { content: ''; position: absolute; left: 0; top: 0.65em; width: 7px; height: 7px; border-radius: 50%; background: var(--teal); }
    .title-slide { text-align: center !important; display: flex !important; flex-direction: column; justify-content: center; align-items: center; }
    .title-slide .subtitle { font-size: 1.4em; color: var(--teal); font-weight: 600; margin-top: 0.3em; }
    .title-slide .author { font-size: 0.8em; color: var(--slate); margin-top: 2em; }
    .title-slide .author strong { color: var(--white); font-weight: 600; display: block; font-size: 1.2em; margin-bottom: 0.3em; }
    .section-divider { text-align: center !important; display: flex !important; flex-direction: column; justify-content: center; align-items: center; }
    .section-divider h2 { font-size: 2.5em; background: linear-gradient(135deg, var(--teal), var(--purple)); -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text; }
    .tag { display: inline-block; padding: 4px 14px; border-radius: 20px; font-size: 0.65em; font-weight: 600; margin: 2px; }
    .tag-teal { background: rgba(14,165,233,0.2); color: var(--teal); }
    .tag-emerald { background: rgba(16,185,129,0.2); color: var(--emerald); }
    .tag-amber { background: rgba(245,158,11,0.2); color: var(--amber); }
    .tag-rose { background: rgba(244,63,94,0.2); color: var(--rose); }
    .tag-purple { background: rgba(139,92,246,0.2); color: var(--purple); }
    .two-col { display: grid; grid-template-columns: 1fr 1fr; gap: 30px; margin-top: 0.5em; }
    .three-col { display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 15px; margin-top: 0.5em; }
    .info-box { background: rgba(14,165,233,0.1); border-left: 4px solid var(--teal); border-radius: 0 12px 12px 0; padding: 14px 18px; margin: 0.6em 0; font-size: 0.85em; }
    .warning-box { background: rgba(244,63,94,0.1); border-left: 4px solid var(--rose); border-radius: 0 12px 12px 0; padding: 14px 18px; margin: 0.6em 0; font-size: 0.85em; }
    .pearl-box { background: rgba(245,158,11,0.1); border-left: 4px solid var(--amber); border-radius: 0 12px 12px 0; padding: 14px 18px; margin: 0.6em 0; font-size: 0.85em; }
    .stat-card { background: rgba(255,255,255,0.05); border: 1px solid rgba(255,255,255,0.1); border-radius: 16px; padding: 20px; text-align: center; }
    .stat-card .number { font-size: 2.5em; font-weight: 900; background: linear-gradient(135deg, var(--teal), var(--emerald)); -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text; }
    .stat-card .label { font-size: 0.7em; color: var(--slate); margin-top: 0.3em; text-transform: uppercase; letter-spacing: 0.1em; }
    .reveal table { width: 100%; border-collapse: collapse; font-size: 0.7em; margin-top: 0.5em; }
    .reveal table th { background: rgba(14,165,233,0.2); color: var(--teal); padding: 8px 12px; text-align: left; font-weight: 700; border-bottom: 2px solid var(--teal); }
    .reveal table td { padding: 6px 12px; border-bottom: 1px solid rgba(255,255,255,0.08); }
    .score-bar { width: 100%; height: 10px; background: rgba(255,255,255,0.1); border-radius: 5px; overflow: hidden; margin-top: 0.3em; }
    .score-bar-fill { height: 100%; border-radius: 5px; transition: width 1s ease; }
    .score-bar-fill.excellent { background: linear-gradient(90deg, var(--emerald), var(--teal)); }
    .score-bar-fill.good { background: linear-gradient(90deg, var(--amber), var(--emerald)); }
    .score-bar-fill.poor { background: linear-gradient(90deg, var(--rose), var(--amber)); }
    /* Quiz styles */
    .quiz-container { background: rgba(139,92,246,0.05); border: 1px solid rgba(139,92,246,0.2); border-radius: 20px; padding: 28px; margin-top: 0.3em; }
    .quiz-question { font-size: 1.05em; font-weight: 600; margin-bottom: 0.8em; color: var(--white); line-height: 1.5; }
    .quiz-options { display: grid; gap: 10px; }
    .quiz-option { background: rgba(255,255,255,0.05); border: 2px solid rgba(255,255,255,0.1); border-radius: 12px; padding: 12px 18px; cursor: pointer; transition: all 0.3s ease; font-size: 0.82em; display: flex; align-items: center; gap: 12px; }
    .quiz-option:hover { background: rgba(139,92,246,0.1); border-color: var(--purple); }
    .quiz-option.correct { background: rgba(16,185,129,0.2) !important; border-color: var(--emerald) !important; }
    .quiz-option.incorrect { background: rgba(244,63,94,0.15) !important; border-color: var(--rose) !important; }
    .quiz-option .option-letter { width: 28px; height: 28px; border-radius: 50%; background: rgba(255,255,255,0.1); display: flex; align-items: center; justify-content: center; font-weight: 700; font-size: 0.85em; flex-shrink: 0; }
    .quiz-feedback { margin-top: 0.8em; padding: 12px 18px; border-radius: 12px; font-size: 0.8em; display: none; }
    .quiz-feedback.show { display: block; }
    .quiz-feedback.correct-fb { background: rgba(16,185,129,0.15); border: 1px solid var(--emerald); color: var(--emerald); }
    .quiz-feedback.incorrect-fb { background: rgba(244,63,94,0.1); border: 1px solid var(--rose); color: var(--rose); }
    .img-container { text-align: center; margin-top: 0.5em; }
    .img-container img { max-width: 90%; max-height: 55vh; border-radius: 12px; box-shadow: 0 8px 32px rgba(0,0,0,0.3); }
    .small { font-size: 0.75em; }
    .tiny { font-size: 0.6em; color: var(--slate); }
    .highlight { color: var(--teal); font-weight: 700; }
    .highlight-amber { color: var(--amber); font-weight: 700; }
    .highlight-rose { color: var(--rose); font-weight: 700; }
    .highlight-emerald { color: var(--emerald); font-weight: 700; }
    .key-icon { color: var(--amber); margin-right: 6px; }
    .danger-icon { color: var(--rose); margin-right: 6px; }
    .reveal .slide-background { background: var(--navy); }
    .reveal .progress { height: 4px; }
    .reveal .progress span { background: linear-gradient(90deg, var(--teal), var(--purple)); }
    .reveal .controls .controls-arrow { color: var(--teal); }
    #score-tracker { position: fixed; bottom: 60px; right: 20px; background: rgba(10,22,40,0.9); border: 1px solid rgba(139,92,246,0.3); border-radius: 12px; padding: 8px 16px; font-size: 14px; color: var(--purple); font-weight: 600; z-index: 100; backdrop-filter: blur(10px); }
    .badge { position: absolute; top: 20px; right: 20px; background: rgba(14,165,233,0.15); border: 1px solid rgba(14,165,233,0.3); border-radius: 20px; padding: 6px 16px; font-size: 0.55em; color: var(--teal); font-weight: 600; }
    .stage-flow { display: flex; align-items: center; gap: 6px; margin: 0.5em 0; flex-wrap: wrap; }
    .stage-box { background: rgba(14,165,233,0.15); border: 1px solid rgba(14,165,233,0.3); border-radius: 12px; padding: 10px 16px; text-align: center; min-width: 90px; flex: 1; }
    .stage-box .stage-num { font-size: 1.6em; font-weight: 900; color: var(--teal); }
    .stage-box .stage-desc { font-size: 0.55em; color: var(--slate); margin-top: 0.2em; }
    .stage-arrow { color: var(--teal); font-size: 1em; }
    @media (max-width: 768px) { .two-col, .three-col { grid-template-columns: 1fr; } .reveal h1 { font-size: 1.8em; } .reveal .slides section { padding: 20px 30px; } }
  </style>
</head>
<body>
  <div id="score-tracker"><i class="fas fa-trophy"></i> Score: <span id="quiz-score">0</span>/<span id="quiz-total">0</span></div>

  <div class="reveal">
    <div class="slides">

      <!-- ===== TITLE ===== -->
      <section class="title-slide" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <span class="tag tag-teal"><i class="fas fa-graduation-cap"></i> INTERACTIVE SURGICAL EDUCATION</span>
        <h1>Pediatric Renal Masses</h1>
        <div class="subtitle">A Question-Driven Review</div>
        <div class="author">
          <strong>Mikael Petrosyan, MD, MBA, FACS, FAAP</strong>
          Division Chief, General &amp; Thoracic Surgery<br>
          Children's National Hospital | George Washington University<br>
          <span style="color:var(--teal)">Surgucation</span>
        </div>
        <div class="tiny" style="margin-top:1.5em">
          <i class="fas fa-keyboard"></i> Arrow keys to navigate &nbsp;|&nbsp; <i class="fas fa-expand"></i> F for fullscreen &nbsp;|&nbsp; <i class="fas fa-sticky-note"></i> S for speaker notes
        </div>
        <aside class="notes">Welcome. This is an interactive, question-driven review of pediatric renal masses. Instead of a traditional lecture, we'll work through clinical scenarios and questions together. You'll answer first, then we'll discuss the teaching points. Stay engaged — there will be scoring at the end! Press S to see speaker notes throughout.</aside>
      </section>

      <!-- ===== FORMAT INTRO ===== -->
      <section style="text-align:center; display:flex; flex-direction:column; justify-content:center; align-items:center;">
        <h2>How This Works</h2>
        <div style="max-width:700px; text-align:left; margin-top:1em">
          <div class="info-box"><i class="fas fa-question-circle" style="color:var(--purple)"></i> <strong>Step 1:</strong> A clinical question appears — think through your answer</div>
          <div class="pearl-box"><i class="fas fa-mouse-pointer" style="color:var(--amber)"></i> <strong>Step 2:</strong> Click your answer to see if you're right</div>
          <div class="info-box"><i class="fas fa-book-open" style="color:var(--teal)"></i> <strong>Step 3:</strong> Teaching content follows — deep dive into the topic</div>
          <div style="text-align:center; margin-top:1.5em; font-size:0.9em; color:var(--slate)">
            <i class="fas fa-redo"></i> &nbsp;This cycle repeats throughout the presentation.<br>
            <strong style="color:var(--purple)">Your score is tracked — see how you do!</strong>
          </div>
        </div>
        <aside class="notes">Explain the format: each section starts with a clinical question, then reveals the answer and teaching content. This keeps the audience engaged and thinking rather than passively listening. Encourage them to commit to an answer before clicking.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 1: What is the most common pediatric renal tumor? -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 1</h2>
        <div class="quiz-container" id="q1">
          <div class="quiz-question">A 3-year-old healthy-appearing girl is found to have a firm, non-tender abdominal mass during a bath. CT shows a large intrarenal mass with a "claw sign" and no calcification. What is the most likely diagnosis?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q1')"><div class="option-letter">A</div><div>Neuroblastoma</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q1')"><div class="option-letter">B</div><div>Wilms tumor (nephroblastoma)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q1')"><div class="option-letter">C</div><div>Congenital mesoblastic nephroma</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q1')"><div class="option-letter">D</div><div>Renal cell carcinoma</div></div>
          </div>
          <div class="quiz-feedback" id="q1-feedback"></div>
        </div>
        <aside class="notes">Classic board question. Healthy child + painless abdominal mass + claw sign + no calcification = Wilms tumor. Neuroblastoma children are ill-appearing with 60-70% calcification. CMN presents in infants under 3 months. RCC is in adolescents 9-15 years. Give them time to think before revealing.</aside>
      </section>

      <!-- TEACH 1: Wilms Tumor Overview + Big Picture -->
      <section>
        <h2>Wilms Tumor: The Big Picture</h2>
        <div class="three-col">
          <div class="stat-card"><div class="number">>90%</div><div class="label">of pediatric renal tumors</div></div>
          <div class="stat-card"><div class="number">3 yrs</div><div class="label">median age at diagnosis</div></div>
          <div class="stat-card"><div class="number">>90%</div><div class="label">5-year overall survival</div></div>
        </div>
        <div class="pearl-box" style="margin-top:1em">
          <i class="fas fa-gem key-icon"></i> <strong>Classic Scenario:</strong> A <span class="highlight-amber">healthy-appearing child</span> with an incidentally discovered, firm, smooth, non-tender abdominal mass found during bathing. This is the #1 way WT presents (83%).
        </div>
        <div class="warning-box">
          <i class="fas fa-exchange-alt danger-icon"></i> <strong>WT vs Neuroblastoma:</strong>
          WT = healthy child, 5-10% calcification, intrarenal "claw sign" &nbsp;|&nbsp;
          NB = ill child, 60-70% calcification, adrenal/paraspinal, crosses midline
        </div>
        <aside class="notes">Key teaching: Wilms tumor is 90%+ of pediatric renal tumors. 500-600 new US cases/year. Incidence 5.7 per million children, highest in African Americans (7.1/M). 75%+ present ages 1-5. Additional symptoms: abdominal pain 37%, fever 23%, hematuria 25%, hypertension 25%. ~10% have acquired von Willebrand disease — always check coags. Don't forget urine catecholamines (HVA/VMA) to rule out neuroblastoma.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 2: Age-Based Classification -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 2</h2>
        <div class="quiz-container" id="q2">
          <div class="quiz-question">A 2-month-old boy presents with a palpable abdominal mass. Ultrasound reveals a solid renal tumor. What is the most likely diagnosis?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q2')"><div class="option-letter">A</div><div>Wilms tumor</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q2')"><div class="option-letter">B</div><div>Congenital mesoblastic nephroma</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q2')"><div class="option-letter">C</div><div>Clear cell sarcoma of the kidney</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q2')"><div class="option-letter">D</div><div>Renal cell carcinoma</div></div>
          </div>
          <div class="quiz-feedback" id="q2-feedback"></div>
        </div>
        <aside class="notes">Age is your #1 filter. A 2-month-old = think CMN first. CMN is the most common renal tumor in infants under 3 months with a median age of 1 month. Wilms peaks at 1-5 years, CCSK at 2-4 years, RCC at 9-15 years.</aside>
      </section>

      <!-- TEACH 2: Age-Based Classification -->
      <section>
        <h2>Age Is Your First Filter</h2>
        <div class="three-col">
          <div class="stat-card" style="border-color: rgba(16,185,129,0.3)">
            <div style="font-size:1.8em"><i class="fas fa-baby" style="color:var(--emerald)"></i></div>
            <div style="font-weight:800; color:var(--emerald)">Neonates (&lt;3 mo)</div>
            <div class="small" style="margin-top:0.5em; text-align:left">
              <strong>CMN</strong> — #1 renal tumor<br>Median: 1 month<br>Male 2:1<br>
              <span class="tag tag-emerald">Classic</span> <span class="tag tag-emerald">Cellular</span> <span class="tag tag-emerald">Mixed</span>
            </div>
          </div>
          <div class="stat-card" style="border-color: rgba(14,165,233,0.3)">
            <div style="font-size:1.8em"><i class="fas fa-child" style="color:var(--teal)"></i></div>
            <div style="font-weight:800; color:var(--teal)">Children (1&ndash;5 yrs)</div>
            <div class="small" style="margin-top:0.5em; text-align:left">
              <strong>Wilms Tumor</strong> — 90%+<br>Median: 3 years<br>
              <span class="tag tag-teal">FHWT</span> <span class="tag tag-rose">Anaplastic</span><br>
              Also: CCSK (2-4yr), MRTK (&lt;1yr)
            </div>
          </div>
          <div class="stat-card" style="border-color: rgba(139,92,246,0.3)">
            <div style="font-size:1.8em"><i class="fas fa-user" style="color:var(--purple)"></i></div>
            <div style="font-weight:800; color:var(--purple)">Adolescents (9&ndash;15 yrs)</div>
            <div class="small" style="margin-top:0.5em; text-align:left">
              <strong>RCC</strong> — 2-6% of renal tumors<br>
              <span class="tag tag-purple">MiT-RCC (36-56%)</span><br>
              <span class="tag tag-purple">Papillary</span> <span class="tag tag-purple">Clear cell</span>
            </div>
          </div>
        </div>
        <div class="img-container" style="margin-top:0.8em">
          <img src="assets/img/clinical-comparison.png" alt="Pediatric Renal Masses Comparison" style="max-height:32vh">
        </div>
        <aside class="notes">Emphasize: always think about age first. Neonates = CMN, Toddlers = Wilms, Adolescents = RCC. But also remember the rare but deadly ones: rhabdoid tumor peaks under 1 year, and clear cell sarcoma peaks at 2-4 years. CMN subtypes: Classic 45% (EGFR ITD, 0% recurrence), Cellular 21% (ETV6-NTRK3 fusion, higher recurrence), Mixed 29%. CMN overall survival 96-100%.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 3: Genetic Syndromes -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 3</h2>
        <div class="quiz-container" id="q3">
          <div class="quiz-question">A child with WAGR syndrome is being followed with surveillance. How often should screening ultrasounds be performed, and until what age?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q3')"><div class="option-letter">A</div><div>Every 6 months until age 5</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q3')"><div class="option-letter">B</div><div>Every 3 months until age 7</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q3')"><div class="option-letter">C</div><div>Every 12 months until age 10</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q3')"><div class="option-letter">D</div><div>Every 3 months until age 4</div></div>
          </div>
          <div class="quiz-feedback" id="q3-feedback"></div>
        </div>
        <aside class="notes">Per NCCN guidelines: Q3 months physical exam + renal US until age 7 for all high-risk syndromes. Rationale: 90-98% of Wilms in syndromic patients occurs by age 7. In WAGR specifically, 90% by age 4 and 98% by age 7, leaving only 1% residual risk after age 7.</aside>
      </section>

      <!-- TEACH 3: Genetic Predisposition -->
      <section>
        <h2>Genetic Predisposition (10&ndash;33% of WT)</h2>
        <div class="two-col">
          <div>
            <h3 class="highlight-rose"><i class="fas fa-exclamation-triangle"></i> High-Risk Syndromes</h3>
            <table>
              <thead><tr><th>Syndrome</th><th>WT Risk</th><th>Key Features</th></tr></thead>
              <tbody>
                <tr><td><strong>WAGR</strong></td><td class="highlight-rose">45&ndash;60%</td><td><small>Wilms, Aniridia, GU anomalies, intellectual disability</small></td></tr>
                <tr><td><strong>Denys-Drash</strong></td><td class="highlight-rose">~90%</td><td><small>DSD, mesangial sclerosis, renal failure</small></td></tr>
                <tr><td><strong>Perlman</strong></td><td class="highlight-rose">High</td><td><small>Overgrowth, organomegaly, characteristic facies</small></td></tr>
              </tbody>
            </table>
            <h3 style="margin-top:0.8em" class="highlight-amber"><i class="fas fa-exclamation-circle"></i> Moderate-Risk</h3>
            <table>
              <thead><tr><th>Syndrome</th><th>Features</th></tr></thead>
              <tbody>
                <tr><td><strong>Beckwith-Wiedemann</strong></td><td><small>Macroglossia, hemihyperplasia (~5% of WT)</small></td></tr>
                <tr><td><strong>Frasier / Li-Fraumeni</strong></td><td><small>WT1 splice site / TP53 mutations</small></td></tr>
              </tbody>
            </table>
          </div>
          <div>
            <div class="warning-box">
              <strong>Screening Protocol (NCCN v2.2025):</strong><br>
              Physical exam + renal US <strong>every 3 months until age 7</strong><br>
              <small>Rationale: 90&ndash;98% of syndromic WT occurs by age 7</small>
            </div>
            <div class="pearl-box">
              <i class="fas fa-gem key-icon"></i> <strong>Any child with aniridia</strong> &rarr; check for WT1 deletion at 11p13 &rarr; WAGR syndrome
            </div>
            <div class="info-box">
              <strong>Key Genetics:</strong><br>
              WT1 (11p13) &mdash; WAGR, Denys-Drash<br>
              WT2/11p15 (IGF2) &mdash; Beckwith-Wiedemann<br>
              CTNNB1 (&beta;-catenin) &mdash; Wnt pathway, 15%<br>
              WTX (AMER1) &mdash; Xq11.1, ~30%
            </div>
          </div>
        </div>
        <aside class="notes">Genetic predisposition in 10-33% of cases. WAGR: 11p13 deletion affecting WT1 + PAX6 (aniridia). 45-60% WT risk, earlier presentation (median 22mo), 37% bilateral. Denys-Drash: WT1 missense mutations in zinc finger domain. Approaching 90% WT risk, intralobar rests, stromal-predominant tumors. BWS: 11p15.5 imprinting abnormalities. 5-10% WT risk, perilobar rests, more bilateral. Together WT1, WTX, CTNNB1 explain only ~one-third of WT — enormous genetic heterogeneity. Bilateral tumors present earlier reflecting germline predisposition (Knudson two-hit hypothesis).</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 4: Staging -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 4</h2>
        <div class="quiz-container" id="q4">
          <div class="quiz-question">A Wilms tumor is biopsied prior to removal. The tumor is otherwise limited to the kidney with no lymph node involvement. What is the COG stage?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q4')"><div class="option-letter">A</div><div>Stage I</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q4')"><div class="option-letter">B</div><div>Stage II</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q4')"><div class="option-letter">C</div><div>Stage III</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q4')"><div class="option-letter">D</div><div>Stage IV</div></div>
          </div>
          <div class="quiz-feedback" id="q4-feedback"></div>
        </div>
        <aside class="notes">This is a classic trap question. Biopsy before removal = automatic Stage III per COG criteria, regardless of all other factors. This is why COG prefers upfront surgery without preceding biopsy. Other Stage III triggers: LN involvement, spillage, peritoneal implants, removed in more than one piece, positive margins.</aside>
      </section>

      <!-- TEACH 4: COG Staging -->
      <section>
        <h2>COG Staging System</h2>
        <div class="badge">Children's Oncology Group</div>
        <div class="stage-flow">
          <div class="stage-box"><div class="stage-num">I</div><div class="stage-desc">Limited to kidney<br>Completely resected<br>Capsule intact</div></div>
          <div class="stage-arrow"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box"><div class="stage-num">II</div><div class="stage-desc">Beyond kidney<br>Completely resected<br>No residual</div></div>
          <div class="stage-arrow"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box"><div class="stage-num">III</div><div class="stage-desc">Residual in abdomen<br>LN+, spillage, biopsy<br>Positive margins</div></div>
          <div class="stage-arrow"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box"><div class="stage-num">IV</div><div class="stage-desc">Hematogenous mets<br>Lung, liver, bone<br>Distant LN</div></div>
          <div class="stage-arrow"><i class="fas fa-chevron-right"></i></div>
          <div class="stage-box" style="border-color:var(--amber)"><div class="stage-num" style="color:var(--amber)">V</div><div class="stage-desc">Bilateral<br>at diagnosis<br>Each side I-IV</div></div>
        </div>
        <div class="warning-box" style="margin-top:0.5em">
          <strong>Stage III Triggers (know these cold):</strong> LN involvement, peritoneal implants/penetration, tumor spillage, biopsy before removal, removed in &gt;1 piece, positive margins, unresectable tumor
        </div>
        <aside class="notes">COG staging drives treatment intensity. Stage I: limited to kidney, completely resected, capsule intact, no biopsy before removal, renal sinus vessels clear, negative margins and nodes. Stage II: extends beyond kidney but completely excised with negative margins and nodes. Stage III: residual nonhematogenous tumor in abdomen — the catch-all for anything that goes wrong. The biopsy-before-removal trap is a favorite board question. Stage IV: hematogenous metastases — lungs most common, then liver, bone, brain. Stage V: bilateral at diagnosis, each kidney staged independently. Stage determines chemo regimen and whether radiation is needed.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 5: COG vs SIOP -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 5</h2>
        <div class="quiz-container" id="q5">
          <div class="quiz-question">Which approach to Wilms tumor management uses neoadjuvant chemotherapy before surgery as the standard protocol?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q5')"><div class="option-letter">A</div><div>COG (Children's Oncology Group) — North America</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q5')"><div class="option-letter">B</div><div>SIOP (International Society of Paediatric Oncology) — Europe</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q5')"><div class="option-letter">C</div><div>Both use neoadjuvant chemotherapy as standard</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q5')"><div class="option-letter">D</div><div>Neither — surgery first is universal</div></div>
          </div>
          <div class="quiz-feedback" id="q5-feedback"></div>
        </div>
        <aside class="notes">SIOP uses neoadjuvant chemo as standard (4 weeks localized, 6 weeks metastatic). COG uses upfront surgery except in specific circumstances (bilateral, unresectable, IVC thrombus above hepatic veins, solitary kidney). Both achieve >90% survival for favorable histology.</aside>
      </section>

      <!-- TEACH 5: COG vs SIOP + Histology -->
      <section>
        <h2>Two Philosophies, Equal Outcomes</h2>
        <div class="two-col">
          <div>
            <h3><i class="fas fa-flag-usa" style="color:var(--teal)"></i> COG (North America)</h3>
            <ul class="small">
              <li><strong>Upfront surgery</strong> &rarr; then chemo</li>
              <li>Unaltered histology + molecular info</li>
              <li>Identifies anaplasia pre-chemo</li>
              <li>Risk: 14.6% tumor rupture</li>
            </ul>
            <h3 style="margin-top:0.5em"><i class="fas fa-globe-europe" style="color:var(--purple)"></i> SIOP (Europe)</h3>
            <ul class="small">
              <li><strong>Neoadjuvant chemo</strong> &rarr; then surgery</li>
              <li>Tumor shrinks, easier resection</li>
              <li><strong>0% tumor rupture</strong></li>
              <li>Risk: altered histology, may miss anaplasia</li>
            </ul>
          </div>
          <div>
            <h3>Histologic Classification</h3>
            <div class="info-box">
              <strong class="highlight-emerald">Favorable Histology (90%):</strong><br>
              Triphasic: blastemal + epithelial + stromal<br>
              No anaplasia &rarr; <span class="highlight-emerald">&gt;90% 5-yr OS</span>
            </div>
            <div class="warning-box">
              <strong class="highlight-rose">Anaplastic (5-10%):</strong><br>
              <strong>Focal:</strong> Confined foci, &lt;15mm, not in vessels &rarr; better prognosis<br>
              <strong>Diffuse:</strong> Multifocal, beyond capsule, TP53 mutations &rarr; <span class="highlight-rose">29-45% OS Stage IV</span>
            </div>
            <div class="pearl-box">
              <i class="fas fa-gem key-icon"></i> <strong>SIOP Post-Chemo Risk:</strong><br>
              <span class="tag tag-emerald">Low</span> Completely necrotic<br>
              <span class="tag tag-teal">Intermediate</span> Epithelial, stromal, mixed<br>
              <span class="tag tag-rose">High</span> Blastemal predominant, DA
            </div>
          </div>
        </div>
        <aside class="notes">Both approaches yield equivalent survival >90% for favorable histology — this is the key message. COG advantage: unaltered histology and molecular data for precise risk stratification. SIOP advantage: 0% rupture, easier surgery, lower complications. COG uses neoadjuvant chemo selectively for: bilateral disease, unresectable tumors, IVC thrombus above hepatic veins, solitary kidney. Histology: FHWT is 90% of cases with triphasic pattern. Anaplasia (5-10%) defined by markedly enlarged hyperchromatic nuclei and abnormal mitotic figures. Focal = better, Diffuse = bad (TP53 mutations = chemoresistance). SIOP classifies AFTER chemo: blastemal predominance after chemo = high risk (blastema survived the chemo).</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 6: Treatment -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 6</h2>
        <div class="quiz-container" id="q6">
          <div class="quiz-question">Diffuse anaplasia in Wilms tumor is associated with mutations in which gene, conferring chemoresistance?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q6')"><div class="option-letter">A</div><div>WT1</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q6')"><div class="option-letter">B</div><div>CTNNB1 (beta-catenin)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q6')"><div class="option-letter">C</div><div>TP53</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q6')"><div class="option-letter">D</div><div>SMARCB1 (INI1)</div></div>
          </div>
          <div class="quiz-feedback" id="q6-feedback"></div>
        </div>
        <aside class="notes">TP53 mutations are the hallmark of anaplastic histology. They predict chemoresistance — which is why diffuse anaplasia has such poor outcomes. WT1 = WAGR/Denys-Drash. CTNNB1 = Wnt pathway activation. SMARCB1 = rhabdoid tumor.</aside>
      </section>

      <!-- TEACH 6: Chemotherapy + Molecular -->
      <section>
        <h2>Treatment: Risk-Stratified Chemotherapy</h2>
        <table style="font-size:0.65em">
          <thead><tr><th>Regimen</th><th>Risk</th><th>Agents</th><th>Key Point</th></tr></thead>
          <tbody>
            <tr><td><strong>EE4A</strong></td><td><span class="tag tag-emerald">Very Low/Low</span></td><td>VCR + Dactinomycin</td><td>18 weeks, no doxorubicin</td></tr>
            <tr><td><strong>DD4A</strong></td><td><span class="tag tag-teal">Standard</span></td><td>VCR + Dact + Doxorubicin</td><td>24 weeks, cumulative doxo 150 mg/m²</td></tr>
            <tr><td><strong>Regimen M</strong></td><td><span class="tag tag-amber">Higher</span></td><td>DD4A + Cyclo + Etoposide</td><td>For adverse molecular markers</td></tr>
            <tr><td><strong>UH-2</strong></td><td><span class="tag tag-rose">Stage II-IV DA</span></td><td>VCR+Doxo+Cyclo+Carbo+Etop+Irinotecan</td><td>Most toxic WT regimen</td></tr>
          </tbody>
        </table>
        <div class="two-col" style="margin-top:0.8em">
          <div class="info-box">
            <strong>Unfavorable Molecular Markers:</strong>
            <ul class="small">
              <li><strong>1q gain</strong> — most powerful adverse marker</li>
              <li><strong>Combined LOH 1p + 16q</strong> — 3.3x relapse, 12x mortality</li>
              <li><strong>TP53 mutations</strong> — hallmark of anaplasia</li>
            </ul>
          </div>
          <div class="info-box">
            <strong>Radiation Indications:</strong>
            <ul class="small">
              <li>Stage III FHWT: flank/whole-abdomen RT</li>
              <li>Stage IV: whole-lung RT for pulmonary mets</li>
              <li>Timing: 10-14 days post-surgery</li>
            </ul>
          </div>
        </div>
        <aside class="notes">Treatment escalates with risk. EE4A (vincristine + dactinomycin) is the mildest — no doxorubicin, so no cardiotoxicity risk. DD4A adds doxorubicin at cumulative 150 mg/m² — need echo monitoring. Regimen M adds cyclophosphamide and etoposide for patients with adverse molecular markers (1q gain, LOH 1p/16q). UH-2 is the most toxic — used for Stage II-IV diffuse anaplasia with addition of irinotecan. Molecular markers now drive treatment intensity: 1q gain increases relapse 3.3x, combined LOH 1p/16q increases mortality 12x. These can upgrade treatment even in lower-stage disease. Radiation: Stage III FHWT gets flank RT, Stage IV gets lung RT. Goal of modern protocols: de-escalate whenever possible to minimize devastating late effects.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 7: Surgery -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 7</h2>
        <div class="quiz-container" id="q7">
          <div class="quiz-question">What is the most significant risk factor for surgical complications during Wilms tumor nephrectomy?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q7')"><div class="option-letter">A</div><div>Tumor size &ge;10 cm (OR 2.0)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q7')"><div class="option-letter">B</div><div>IVC tumor thrombus extension (OR 3.8)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q7')"><div class="option-letter">C</div><div>Flank/paramedian incision (OR 5.3)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q7')"><div class="option-letter">D</div><div>General surgeon performing nephrectomy (OR 9.0)</div></div>
          </div>
          <div class="quiz-feedback" id="q7-feedback"></div>
        </div>
        <aside class="notes">The answer is general surgeon performing the nephrectomy (OR 9.0) — by far the highest odds ratio for complications. Even higher than IVC extension (3.8x), flank incision (5.3x), or tumor size ≥10cm (2.0x). This data from NWTS-4 strongly supports that Wilms nephrectomy should be done by pediatric surgeons at experienced centers.</aside>
      </section>

      <!-- TEACH 7: Surgical Technique -->
      <section>
        <h2>Surgical Management</h2>
        <div class="two-col">
          <div>
            <h3><i class="fas fa-cut" style="color:var(--teal)"></i> Radical Nephrectomy Steps</h3>
            <ul class="small">
              <li><strong>Transabdominal approach</strong> (preferred over flank — OR 5.3x complication risk with flank)</li>
              <li>Explore: biopsy liver, peritoneal surfaces</li>
              <li>Assess renal vein + IVC for thrombus</li>
              <li><strong>Lymph node sampling: minimum 5 nodes</strong> (hilum, pericaval, para-aortic)</li>
              <li>En bloc nephrectomy without spillage</li>
              <li>Adrenalectomy NOT required if uninvolved</li>
            </ul>
            <div class="warning-box" style="margin-top:0.5em">
              <strong>Complications (NWTS-4: 12.7%):</strong><br>
              SBO 5.1% | Hemorrhage 1.9% | Wound infection 1.9%
            </div>
          </div>
          <div>
            <h3><i class="fas fa-hand-holding-medical" style="color:var(--emerald)"></i> Nephron-Sparing Surgery</h3>
            <div class="info-box">
              <strong>Indications:</strong> Bilateral (Stage V), solitary kidney, predisposing syndromes, high CKD risk
            </div>
            <div class="info-box">
              <strong>Favorable imaging:</strong> Peripheral/polar, preserves &ge;1/3 kidney, no hilar invasion, clear interface
            </div>
            <div class="pearl-box">
              <i class="fas fa-gem key-icon"></i> <strong>NSS protocol:</strong> Neoadjuvant chemo 6-12 weeks &rarr; re-image at week 6 &rarr; surgery within 12 weeks. Never do bilateral nephrectomy upfront.
            </div>
          </div>
        </div>
        <aside class="notes">Surgical management is where we make the biggest difference. Transabdominal approach is mandatory — flank incision carries 5.3x complication risk. Key steps: explore, assess vessels for thrombus, mobilize tumor, ligate ureter low, ligate renal vessels, and critically — LYMPH NODE SAMPLING minimum 5 nodes from hilum, pericaval, para-aortic. Failure to sample nodes can upstage to Stage III. Complete nephrectomy en bloc without spillage. NSS for bilateral tumors, solitary kidney, predisposing syndromes. Protocol: neoadjuvant chemo 6-12 weeks, re-image at week 6, operate within 12 weeks. Goal: preserve at least 1/3 normal kidney. After nephrectomy with 30-50yr follow-up, 40% develop CKD — this is why NSS matters.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 8: Bone Metastases -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 8</h2>
        <div class="quiz-container" id="q8">
          <div class="quiz-question">A child with a renal mass is found to have bone metastases to the spine and pelvis. Which tumor is most associated with osseous spread?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q8')"><div class="option-letter">A</div><div>Wilms tumor (favorable histology)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q8')"><div class="option-letter">B</div><div>Clear cell sarcoma of the kidney</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q8')"><div class="option-letter">C</div><div>Congenital mesoblastic nephroma</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q8')"><div class="option-letter">D</div><div>Renal cell carcinoma</div></div>
          </div>
          <div class="quiz-feedback" id="q8-feedback"></div>
        </div>
        <aside class="notes">Clear cell sarcoma of the kidney is known as the "bone-metastasizing renal tumor of childhood." 23% develop bone metastases to spine, pelvis, ribs. BCOR internal tandem duplications in 85%. Always get a bone scan — unlike standard Wilms workup.</aside>
      </section>

      <!-- TEACH 8: Rare Tumors -->
      <section>
        <h2>Rare But Critical Tumors</h2>
        <div class="two-col">
          <div>
            <h3 style="color:var(--amber)"><i class="fas fa-bone"></i> Clear Cell Sarcoma (CCSK)</h3>
            <ul class="small">
              <li><strong>BCOR</strong> internal tandem duplications (85%)</li>
              <li><span class="highlight-amber">"Bone-metastasizing renal tumor"</span> — 23% get bone mets</li>
              <li>Peak age: 2&ndash;4 years</li>
              <li>Must get <strong>bone scan</strong> at staging</li>
              <li>Requires intensive chemo + radiation</li>
              <li>Late relapses up to 10+ years</li>
            </ul>
          </div>
          <div>
            <h3 style="color:var(--rose)"><i class="fas fa-brain"></i> Rhabdoid Tumor (MRTK)</h3>
            <ul class="small">
              <li><strong>SMARCB1/INI1</strong> loss (22q11.2)</li>
              <li>Median age: <span class="highlight-rose">&lt;1 year</span></li>
              <li>Most aggressive pediatric renal tumor</li>
              <li><span class="highlight-rose">~25% synchronous brain tumors</span> (AT/RT)</li>
              <li>Must get <strong>brain MRI</strong> at diagnosis</li>
              <li>Only ~25-40% long-term survival</li>
            </ul>
          </div>
        </div>
        <div class="warning-box" style="margin-top:0.5em">
          <strong>Red Flags:</strong> Renal mass + bone mets &rarr; think CCSK. Infant + renal mass + brain mass &rarr; think rhabdoid. Both require different imaging and more aggressive protocols than Wilms.
        </div>
        <aside class="notes">CCSK: 3-5% of pediatric renal tumors, driven by BCOR ITD in 85%. Called "bone-metastasizing renal tumor" because 23% develop bone mets (spine, pelvis, ribs) — unique among pediatric renal tumors. Can't distinguish from Wilms on imaging — diagnosis requires pathology. Late relapses possible up to 10+ years. Treatment: radical nephrectomy + intensive chemo with doxorubicin + flank radiation. Rhabdoid: SMARCB1/INI1 loss creates dependency on EZH2 (therapeutic target). Most aggressive pediatric renal tumor — median age under 1 year. 25% have synchronous AT/RT brain tumors, so BRAIN MRI IS MANDATORY. Imaging clue: subcapsular crescent-shaped fluid collection + curvilinear calcifications. Prognosis devastating: ~25-40% long-term survival. Tazemetostat (EZH2 inhibitor) showing early promise in Phase I trials.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 9: Pediatric RCC -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 9</h2>
        <div class="quiz-container" id="q9">
          <div class="quiz-question">The most common histological subtype of renal cell carcinoma in children is:</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q9')"><div class="option-letter">A</div><div>Clear cell RCC (predominant in adults)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q9')"><div class="option-letter">B</div><div>Translocation-type RCC (MiT-RCC, TFE3/TFEB)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q9')"><div class="option-letter">C</div><div>Papillary RCC</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q9')"><div class="option-letter">D</div><div>Chromophobe RCC</div></div>
          </div>
          <div class="quiz-feedback" id="q9-feedback"></div>
        </div>
        <aside class="notes">In children, MiT-RCC (TFE3/TFEB translocation type) accounts for 36-56% — the most common pediatric subtype. This is a key difference from adults where clear cell predominates at ~70%. MiT-RCC involves translocations at Xp11.2 (TFE3) or 6p21 (TFEB). Diagnosis: nuclear TFE3 IHC or FISH.</aside>
      </section>

      <!-- TEACH 9: Pediatric RCC -->
      <section>
        <h2>Pediatric Renal Cell Carcinoma</h2>
        <div class="two-col">
          <div>
            <ul class="small">
              <li>2&ndash;6% of pediatric renal tumors; mean age <span class="highlight">9&ndash;15 years</span></li>
              <li>Incidence increasing: +3.7%/year</li>
              <li>20% present with metastases</li>
            </ul>
            <table style="margin-top:0.5em">
              <thead><tr><th>Subtype</th><th>Pediatric</th><th>Adult</th></tr></thead>
              <tbody>
                <tr><td><strong>MiT-RCC</strong></td><td class="highlight">36&ndash;56%</td><td>Rare</td></tr>
                <tr><td>Papillary</td><td>20&ndash;30%</td><td>~15%</td></tr>
                <tr><td>Clear cell</td><td>6&ndash;23%</td><td class="highlight-rose">~70%</td></tr>
              </tbody>
            </table>
          </div>
          <div>
            <div class="info-box">
              <strong>Treatment:</strong> Surgery is curative for localized disease. Even N1M0 achieves 87% 4-yr OS <strong>without</strong> adjuvant therapy.
            </div>
            <div class="info-box">
              <strong>Metastatic:</strong> Sunitinib (TKI) per SIOP UMBRELLA. Also: axitinib, cabozantinib, nivolumab.
            </div>
            <div style="font-size:0.8em; margin-top:0.8em">
              <div style="display:flex;justify-content:space-between"><span>Localized</span><span class="highlight-emerald">96.8%</span></div>
              <div class="score-bar"><div class="score-bar-fill excellent" style="width:97%"></div></div>
              <div style="display:flex;justify-content:space-between;margin-top:0.3em"><span>Metastatic</span><span class="highlight-rose">45.6%</span></div>
              <div class="score-bar"><div class="score-bar-fill poor" style="width:46%"></div></div>
            </div>
          </div>
        </div>
        <aside class="notes">Pediatric RCC is fundamentally different from adult RCC — different histology, different biology. MiT-RCC (TFE3/TFEB fusions) is the most common subtype in children at 36-56%, while clear cell dominates in adults at 70%. Surgery is the cornerstone — complete resection is curative. Even lymph node-positive disease does well without adjuvant therapy (87% 4-yr OS). RCC is notoriously chemoresistant. For metastatic/unresectable: sunitinib is the recommended TKI. Localized disease has excellent outcomes at 96.8%, but metastatic drops to 45.6%. New 2024-2025 research: targeting PPARGC1A-mediated mitochondrial respiration as a novel approach specifically for translocation RCC.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 10: Lymph Nodes -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 10</h2>
        <div class="quiz-container" id="q10">
          <div class="quiz-question">During Wilms tumor nephrectomy, what is the minimum number of lymph nodes that should be sampled per COG/NCCN guidelines?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q10')"><div class="option-letter">A</div><div>3 nodes</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q10')"><div class="option-letter">B</div><div>5 nodes</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q10')"><div class="option-letter">C</div><div>7 nodes</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q10')"><div class="option-letter">D</div><div>12 nodes</div></div>
          </div>
          <div class="quiz-feedback" id="q10-feedback"></div>
        </div>
        <aside class="notes">Per COG/NCCN: minimum 5 lymph nodes from renal hilum, pericaval, and para-aortic regions. Failure to adequately sample can under-stage the patient. Inadequate lymph node sampling may effectively upstage to Stage III.</aside>
      </section>

      <!-- TEACH 10: Outcomes -->
      <section>
        <h2>Outcomes: The Numbers That Matter</h2>
        <div class="two-col">
          <div>
            <h3>Favorable Histology (5-yr OS)</h3>
            <div style="font-size:0.85em">
              <div style="margin:0.3em 0"><div style="display:flex;justify-content:space-between"><span>Stage I</span><span class="highlight-emerald">96&ndash;97%</span></div><div class="score-bar"><div class="score-bar-fill excellent" style="width:97%"></div></div></div>
              <div style="margin:0.3em 0"><div style="display:flex;justify-content:space-between"><span>Stage II</span><span class="highlight-emerald">93&ndash;94%</span></div><div class="score-bar"><div class="score-bar-fill excellent" style="width:94%"></div></div></div>
              <div style="margin:0.3em 0"><div style="display:flex;justify-content:space-between"><span>Stage III</span><span class="highlight-amber">85&ndash;92%</span></div><div class="score-bar"><div class="score-bar-fill good" style="width:89%"></div></div></div>
              <div style="margin:0.3em 0"><div style="display:flex;justify-content:space-between"><span>Stage IV</span><span class="highlight-amber">84&ndash;89%</span></div><div class="score-bar"><div class="score-bar-fill good" style="width:87%"></div></div></div>
              <div style="margin:0.3em 0"><div style="display:flex;justify-content:space-between"><span>Stage IV Diffuse Anaplasia</span><span class="highlight-rose">29&ndash;45%</span></div><div class="score-bar"><div class="score-bar-fill poor" style="width:37%"></div></div></div>
            </div>
          </div>
          <div>
            <h3>Long-Term Survivorship</h3>
            <div class="warning-box">
              <strong>30&ndash;50 Year Mortality Data:</strong><br>
              75% of excess deaths from:<br>
              &bull; <span class="highlight-rose">50% second malignancies</span> (bowel, breast)<br>
              &bull; <span class="highlight-rose">25% cardiac disease</span><br>
              Cumulative death risk: 5.4% at 30yr &rarr; 22.7% at 50yr
            </div>
            <div class="pearl-box">
              <i class="fas fa-gem key-icon"></i> <strong>Late Effects by Regimen:</strong><br>
              EE4A: neuropathy only<br>
              DD4A: + cardiotoxicity<br>
              Regimen M: + gonadal toxicity, infertility<br>
              Radiation: second cancers, growth impairment
            </div>
          </div>
        </div>
        <aside class="notes">Favorable histology outcomes are excellent across all stages. Even Stage IV FHWT achieves 84-89% — a triumph of multimodal therapy. But diffuse anaplasia Stage IV at 29-45% shows the limits of current treatment. Long-term data is sobering: at 30-50 years, 75% of excess deaths are from second cancers (50%) and cardiac disease (25%). This is why treatment de-escalation for low-risk patients is so critical. Doxorubicin cardiotoxicity is dose-dependent — younger children and females more susceptible. Cyclophosphamide causes gonadal toxicity above 4 g/m². Fertility counseling mandatory before regimens M, I, UH-1, UH-2. All survivors need individualized long-term follow-up per COG LTFU guidelines.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 11: Molecular -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 11</h2>
        <div class="quiz-container" id="q11">
          <div class="quiz-question">Which molecular alteration is characteristically associated with rhabdoid tumor of the kidney?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q11')"><div class="option-letter">A</div><div>ETV6-NTRK3 fusion</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q11')"><div class="option-letter">B</div><div>BCOR internal tandem duplication</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q11')"><div class="option-letter">C</div><div>SMARCB1/INI1 loss (22q11.2)</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q11')"><div class="option-letter">D</div><div>TFE3 translocation (Xp11.2)</div></div>
          </div>
          <div class="quiz-feedback" id="q11-feedback"></div>
        </div>
        <aside class="notes">SMARCB1/INI1 loss at 22q11.2 is the hallmark of rhabdoid tumor. ETV6-NTRK3 = cellular CMN. BCOR ITD = clear cell sarcoma. TFE3 = translocation RCC. This is a molecular matching question — know which mutation goes with which tumor.</aside>
      </section>

      <!-- TEACH 11: Molecular Match + Targeted Therapies -->
      <section>
        <h2>Molecular Signatures &amp; Emerging Therapies</h2>
        <table style="font-size:0.62em">
          <thead><tr><th>Tumor</th><th>Key Molecular Feature</th><th>Targeted Therapy</th><th>Status</th></tr></thead>
          <tbody>
            <tr><td><strong>Wilms (FHWT)</strong></td><td>WT1, WT2, CTNNB1, 1q gain, LOH 1p/16q</td><td>WT1 CAR-T cells</td><td><span class="tag tag-purple">Phase I</span></td></tr>
            <tr><td><strong>Wilms (anaplastic)</strong></td><td>TP53 mutations</td><td>Intensive chemo (UH-2)</td><td><span class="tag tag-teal">Standard</span></td></tr>
            <tr><td><strong>CMN (cellular)</strong></td><td>ETV6-NTRK3 fusion</td><td><span class="highlight">Larotrectinib / Entrectinib</span></td><td><span class="tag tag-emerald">FDA-approved</span></td></tr>
            <tr><td><strong>Clear cell sarcoma</strong></td><td>BCOR ITD (85%)</td><td>Intensive chemo + RT</td><td><span class="tag tag-teal">Standard</span></td></tr>
            <tr><td><strong>Rhabdoid tumor</strong></td><td>SMARCB1/INI1 loss</td><td><span class="highlight">Tazemetostat</span> (EZH2 inhibitor)</td><td><span class="tag tag-amber">Phase I</span></td></tr>
            <tr><td><strong>Pediatric RCC</strong></td><td>TFE3/TFEB fusions</td><td>Sunitinib, Cabozantinib</td><td><span class="tag tag-teal">SIOP UMBRELLA</span></td></tr>
          </tbody>
        </table>
        <div class="two-col" style="margin-top:0.5em">
          <div class="info-box">
            <strong>COG AREN2231 (Current):</strong> Expanded molecular risk stratification integrating LOH 11p15, LOH 1p/16q, 1q gain. Modified Very Low Risk = nephrectomy only if zero adverse biomarkers.
          </div>
          <div class="info-box">
            <strong>Circulating Tumor DNA:</strong> COG studies detecting 1q gain and LOH from blood draws — non-invasive molecular monitoring and early relapse detection.
          </div>
        </div>
        <aside class="notes">This is the future of pediatric renal oncology — molecular-driven precision therapy. Each tumor has its molecular fingerprint: WT1/CTNNB1 for Wilms, ETV6-NTRK3 for cellular CMN, BCOR ITD for CCSK, SMARCB1 loss for rhabdoid, TFE3/TFEB for pediatric RCC. TRK inhibitors (larotrectinib, entrectinib) are FDA-approved tumor-agnostic and show dramatic responses in NTRK fusion-positive cellular CMN. Tazemetostat targets EZH2 dependency created by SMARCB1 loss in rhabdoid tumors. WT1 CAR-T cells in Phase I for Wilms. Circulating tumor DNA is the next frontier — detecting molecular markers from blood draws without needing tumor tissue. The AREN2231 trial is expanding molecular stratification to personalize treatment intensity.</aside>
      </section>

      <!-- ========================================== -->
      <!-- BLOCK 12: Imaging Differential -->
      <!-- ========================================== -->
      <section>
        <h2><i class="fas fa-question-circle" style="color:var(--purple)"></i> Question 12</h2>
        <div class="quiz-container" id="q12">
          <div class="quiz-question">An infant under 1 year has a renal mass with a subcapsular fluid collection on CT and a synchronous brain mass. Which diagnosis must you consider?</div>
          <div class="quiz-options">
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q12')"><div class="option-letter">A</div><div>Wilms tumor with brain metastasis</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, true, 'q12')"><div class="option-letter">B</div><div>Malignant rhabdoid tumor with synchronous AT/RT</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q12')"><div class="option-letter">C</div><div>Clear cell sarcoma with brain metastasis</div></div>
            <div class="quiz-option" onclick="checkAnswer(this, false, 'q12')"><div class="option-letter">D</div><div>Congenital mesoblastic nephroma with metastasis</div></div>
          </div>
          <div class="quiz-feedback" id="q12-feedback"></div>
        </div>
        <aside class="notes">Infant + renal mass + subcapsular fluid + brain mass = rhabdoid tumor with synchronous AT/RT. SMARCB1/INI1 loss drives both the renal and CNS tumors. Subcapsular fluid collection is a characteristic imaging finding for rhabdoid tumor. Brain MRI is mandatory at diagnosis. Wilms rarely metastasizes to brain. CCSK goes to bone preferentially. CMN rarely metastasizes at all.</aside>
      </section>

      <!-- TEACH 12: Imaging Summary -->
      <section>
        <h2>Imaging: Quick Differential Guide</h2>
        <table style="font-size:0.65em">
          <thead><tr><th>Clinical Scenario</th><th>Most Likely Diagnosis</th><th>Key Imaging Finding</th></tr></thead>
          <tbody>
            <tr><td>Neonate + solid renal mass</td><td><strong>CMN</strong></td><td>"Ring sign" on US, "double-layer sign" on CT</td></tr>
            <tr><td>Child 1-5yr + "claw sign" + no calc</td><td><strong>Wilms tumor</strong></td><td>Heterogeneous, well-circumscribed, 9% calc</td></tr>
            <tr><td>Renal mass + bone metastases</td><td><strong>Clear cell sarcoma</strong></td><td>Homogeneous, get bone scan</td></tr>
            <tr><td>Infant + renal mass + subcapsular fluid + brain</td><td><strong>Rhabdoid tumor</strong></td><td>Curvilinear calcifications, get brain MRI</td></tr>
            <tr><td>Adolescent + solid enhancing renal mass</td><td><strong>RCC</strong></td><td>25% calcification, older age</td></tr>
            <tr><td>Crosses midline, encases vessels, 80%+ calc</td><td><strong>Neuroblastoma (adrenal!)</strong></td><td>NOT renal — urine catecholamines</td></tr>
          </tbody>
        </table>
        <div class="pearl-box" style="margin-top:0.8em">
          <i class="fas fa-gem key-icon"></i> <strong>Always assess:</strong> IVC/renal vein thrombus (4-10% of WT, MRI is gold standard), contralateral kidney (bilateral in 5-7%), chest CT for lung mets. Initial workup: US &rarr; CT/MRI abdomen &rarr; chest CT &rarr; urine catecholamines &rarr; labs (CBC, CMP, coags, UA).
        </div>
        <aside class="notes">This table is your rapid-fire differential guide. The key is pattern recognition: age + imaging features = most likely diagnosis. Each tumor has its signature: CMN = ring sign in neonate. Wilms = claw sign in toddler with no calcification. CCSK = bone mets (23%). Rhabdoid = subcapsular fluid + brain mass in infant. RCC = enhancing mass in adolescent. Neuroblastoma = the big differential, but it's NOT renal (adrenal/paraspinal), crosses midline, heavy calcification. Always check urine catecholamines to rule out neuroblastoma.</aside>
      </section>

      <!-- ===== COMPARISON INFOGRAPHIC ===== -->
      <section>
        <h2>The Big Three: Summary</h2>
        <div class="img-container">
          <img src="assets/img/comparison-overview.png" alt="Pediatric Renal Masses: A Clinical Comparison">
        </div>
        <aside class="notes">This infographic summarizes the three most common pediatric renal tumors side by side. Use this as a visual anchor for the key differences in age, presentation, and outcomes.</aside>
      </section>

      <!-- ===== COMPREHENSIVE TABLE ===== -->
      <section>
        <h2>Complete Comparison Table</h2>
        <table style="font-size:0.58em">
          <thead><tr><th>Feature</th><th style="color:var(--teal)">Wilms</th><th style="color:var(--emerald)">CMN</th><th style="color:var(--purple)">RCC</th><th style="color:var(--amber)">CCSK</th><th style="color:var(--rose)">MRTK</th></tr></thead>
          <tbody>
            <tr><td><strong>Peak Age</strong></td><td>1&ndash;5 yr</td><td>&lt;3 mo</td><td>9&ndash;15 yr</td><td>2&ndash;4 yr</td><td>&lt;1 yr</td></tr>
            <tr><td><strong>% Pediatric Renal</strong></td><td>&gt;90%</td><td>3&ndash;10%</td><td>2&ndash;6%</td><td>3&ndash;5%</td><td>1&ndash;2%</td></tr>
            <tr><td><strong>Key Genetics</strong></td><td>WT1, WT2, CTNNB1</td><td>ETV6-NTRK3, EGFR</td><td>TFE3/TFEB</td><td>BCOR ITD</td><td>SMARCB1 loss</td></tr>
            <tr><td><strong>Metastasis</strong></td><td>Lung &gt; liver</td><td>Rare</td><td>Lung, bone</td><td><strong>Bone</strong> (23%)</td><td>Brain (AT/RT)</td></tr>
            <tr><td><strong>Primary Rx</strong></td><td>Surgery + chemo &plusmn; RT</td><td>Surgery alone</td><td>Surgery &plusmn; TKI</td><td>Surgery + chemo + RT</td><td>Multimodal</td></tr>
            <tr><td><strong>5-Year OS</strong></td><td>&gt;90%</td><td>96&ndash;100%</td><td>84.8%</td><td>~75%</td><td>~25-40%</td></tr>
          </tbody>
        </table>
        <aside class="notes">This master comparison table should be committed to memory. Age, genetics, metastatic pattern, treatment, and survival for each tumor. CMN has the best prognosis (96-100%). Rhabdoid has the worst (~25-40%). Wilms is in between with >90% overall but subgroups that do poorly. Know which molecular marker goes with which tumor — this is increasingly tested on boards.</aside>
      </section>

      <!-- ===== KEY TAKEAWAYS ===== -->
      <section>
        <h2><i class="fas fa-star" style="color:var(--amber)"></i> Six Takeaways</h2>
        <div class="pearl-box"><strong>1.</strong> Age is your first filter: Neonates &rarr; CMN | Toddlers &rarr; Wilms | Adolescents &rarr; RCC | Bone mets &rarr; CCSK | Brain + infant &rarr; MRTK</div>
        <div class="pearl-box"><strong>2.</strong> Wilms tumor is >90% of pediatric renal tumors with >90% survival. Know COG staging cold — biopsy before removal = Stage III.</div>
        <div class="pearl-box"><strong>3.</strong> COG vs SIOP: Both work. COG = surgery first (unaltered histology). SIOP = chemo first (0% rupture). Equal survival.</div>
        <div class="pearl-box"><strong>4.</strong> General surgeon performing nephrectomy = 9x complications. Minimum 5 lymph nodes sampled. Transabdominal approach.</div>
        <div class="pearl-box"><strong>5.</strong> Molecular markers (1q gain, LOH 1p/16q, TP53) now drive treatment decisions beyond stage and histology.</div>
        <div class="pearl-box"><strong>6.</strong> Long-term survivors: 75% of excess deaths at 30-50 years from second cancers and cardiac disease. De-escalation matters.</div>
        <aside class="notes">These are the six points you should take away from this presentation. If you remember nothing else, remember these. They cover the core knowledge needed for clinical practice and board examinations.</aside>
      </section>

      <!-- ===== FINAL SCORE ===== -->
      <section class="section-divider" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <h2>Your Final Score</h2>
        <div id="final-score" style="font-size:4em; font-weight:900; margin:0.3em 0">
          <span id="final-correct">0</span>/<span id="final-total">12</span>
        </div>
        <div id="final-message" style="font-size:1.2em; color:var(--slate)">Complete all 12 questions to see your score!</div>
        <div id="final-bar" style="max-width:400px; margin:1em auto">
          <div class="score-bar"><div class="score-bar-fill excellent" id="final-bar-fill" style="width:0%"></div></div>
        </div>
        <aside class="notes">Review the final score with the audience. Discuss any questions that were commonly missed. Use this as a springboard for further discussion.</aside>
      </section>

      <!-- ===== REFERENCES ===== -->
      <section>
        <h2>Key References</h2>
        <div style="font-size:0.48em; columns:2; column-gap:25px; line-height:1.8; color:var(--slate)">
          <p>1. NCCN Wilms Tumor (Nephroblastoma), Version 2.2025</p>
          <p>2. Espinoza AF, et al. Cancer Medicine. 2025;14(3):e70598</p>
          <p>3. Nakata K, et al. Int J Cancer. 2020;147(12):3313-3327</p>
          <p>4. Hol JA, et al. J Clin Oncol. 2022;40(17):1892-1902</p>
          <p>5. van der Beek JN, et al. Int J Cancer. 2021;148(11):2724-2735</p>
          <p>6. Davick JJ, et al. Annals of Surgery. 2025</p>
          <p>7. Geller JI, et al. Cancer. 2020;126(23):5156-5164</p>
          <p>8. Ritchey ML, et al. J Am Coll Surg. 2001;192(1):63-8</p>
          <p>9. Vujani&#263; GM, et al. Int J Cancer. 2021;149(6):1332-1340</p>
          <p>10. Wong KF, et al. J Clin Oncol. 2016;34(15):1772-9</p>
          <p>11. COG Blueprint for Research: Renal Tumors. PMC 2023</p>
          <p>12. UMBRELLA SIOP-RTSG 2016. Nat Rev Urol. 2018</p>
          <p>13. Sprokkerieft J, et al. Cancer Med. 2024;13(1):e6782</p>
          <p>14. Raymakers-Janssen, et al. Pediatr Nephrol. 2025</p>
          <p>15. Hudson MM, et al. Pediatrics. 2021;148(3)</p>
        </div>
      </section>

      <!-- ===== CLOSING ===== -->
      <section class="title-slide" data-background-gradient="radial-gradient(ellipse at center, #0f2744, #0a1628)">
        <h1 style="font-size:2em">Thank You</h1>
        <div class="subtitle">Questions &amp; Discussion</div>
        <div class="author" style="margin-top:1.5em">
          <strong>Mikael Petrosyan, MD, MBA, FACS, FAAP</strong>
          Division Chief, General &amp; Thoracic Surgery<br>
          Children's National Hospital<br><br>
          <span class="tag tag-teal"><i class="fab fa-youtube"></i> Surgucation</span>
          <span class="tag tag-purple"><i class="fas fa-globe"></i> surgucation.com</span>
        </div>
        <aside class="notes">Thank everyone for their participation. Open the floor for questions and discussion. Encourage them to review any topics they found challenging and to use the presentation as a study reference — it's always available at the URL.</aside>
      </section>

    </div>
  </div>

  <script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.js"></script>
  <script>
    Reveal.initialize({
      hash: true, slideNumber: 'c/t', progress: true, controls: true,
      center: false, transition: 'slide', width: 1280, height: 720,
      margin: 0.04, pdfSeparateFragments: false,
    });

    let score = 0, totalAnswered = 0;
    const totalQuestions = 12;
    const answered = {};

    const explanations = {
      q1: { correct: "Correct! Healthy child + painless mass + claw sign + no calcification = Wilms tumor. Neuroblastoma kids are ill with 60-70% calcification. CMN is neonates. RCC is adolescents.", incorrect: "The answer is <strong>Wilms tumor</strong>. Key clues: healthy child (age 3), firm non-tender mass found incidentally, claw sign (intrarenal), no calcification. Neuroblastoma: ill-appearing, 60-70% calc. CMN: infants <3mo. RCC: adolescents 9-15yr." },
      q2: { correct: "Correct! CMN is the #1 renal tumor in infants under 3 months. Median age 1 month. Wilms peaks at 1-5 years.", incorrect: "The answer is <strong>CMN</strong>. It's the most common renal tumor in infants <3 months (median 1 month). Wilms peaks at 1-5yr, CCSK at 2-4yr, RCC at 9-15yr." },
      q3: { correct: "Correct! Q3 months until age 7 per NCCN. Rationale: 90-98% of syndromic WT occurs by age 7, leaving only ~1% residual risk.", incorrect: "The answer is <strong>every 3 months until age 7</strong>. Per NCCN v2.2025: physical exam + renal US Q3 months until age 7 for WAGR, Denys-Drash, BWS, and other high-risk syndromes." },
      q4: { correct: "Correct! Biopsy before removal = automatic Stage III per COG, regardless of other findings. This is a classic board trap!", incorrect: "The answer is <strong>Stage III</strong>. Per COG: biopsy before removal automatically upgrades to Stage III. Other triggers: LN+, spillage, peritoneal implants, removed in >1 piece, positive margins." },
      q5: { correct: "Correct! SIOP uses neoadjuvant chemo as standard (4wk localized, 6wk metastatic). COG does upfront surgery except for bilateral/unresectable/IVC thrombus.", incorrect: "The answer is <strong>SIOP</strong>. SIOP gives preoperative chemotherapy as standard protocol. COG does upfront surgery then risk-adapted chemo. Both achieve >90% survival for favorable histology." },
      q6: { correct: "Correct! TP53 mutations are the hallmark of anaplasia, conferring chemoresistance. This explains why diffuse anaplasia has such poor outcomes.", incorrect: "The answer is <strong>TP53</strong>. TP53 mutations drive anaplastic histology and chemoresistance. WT1 = WAGR/Denys-Drash. CTNNB1 = Wnt pathway. SMARCB1 = rhabdoid tumor." },
      q7: { correct: "Correct! General surgeon performing nephrectomy = OR 9.0 — the single highest risk factor, even above IVC extension (3.8) or flank incision (5.3).", incorrect: "The answer is <strong>general surgeon</strong> (OR 9.0). Higher than IVC thrombus (3.8), flank incision (5.3), or tumor ≥10cm (2.0). Wilms nephrectomy should be done by pediatric surgeons." },
      q8: { correct: "Correct! CCSK is the 'bone-metastasizing renal tumor of childhood.' BCOR ITD in 85%. 23% develop bone mets to spine, pelvis, ribs. Always get a bone scan!", incorrect: "The answer is <strong>Clear cell sarcoma</strong>. Known as the 'bone-metastasizing renal tumor' with BCOR ITD in 85%. 23% get bone mets. Wilms rarely goes to bone. Always get a bone scan for CCSK." },
      q9: { correct: "Correct! MiT-RCC (TFE3/TFEB) accounts for 36-56% of pediatric RCC — unlike adults where clear cell dominates at ~70%. A critical distinction!", incorrect: "The answer is <strong>MiT-RCC (translocation type)</strong>. In children: TFE3/TFEB fusions at 36-56%, papillary 20-30%, clear cell only 6-23%. Adults: clear cell ~70%. Completely different biology." },
      q10: { correct: "Correct! Minimum 5 nodes from renal hilum, pericaval, and para-aortic regions per COG/NCCN. Inadequate sampling may under-stage the tumor.", incorrect: "The answer is <strong>5 nodes</strong>. Per COG/NCCN: minimum 5 lymph nodes from hilum, pericaval, and para-aortic regions for accurate staging." },
      q11: { correct: "Correct! SMARCB1/INI1 loss at 22q11.2 is the hallmark of rhabdoid tumor. ~25% have synchronous AT/RT. Loss of INI1 staining on IHC is diagnostic.", incorrect: "The answer is <strong>SMARCB1/INI1 loss</strong>. ETV6-NTRK3 = cellular CMN. BCOR ITD = clear cell sarcoma. TFE3 = translocation RCC. SMARCB1 loss = rhabdoid tumor." },
      q12: { correct: "Correct! Infant + renal mass + subcapsular fluid + brain mass = rhabdoid tumor with synchronous AT/RT. SMARCB1/INI1 loss drives both tumors. Brain MRI mandatory!", incorrect: "The answer is <strong>rhabdoid tumor with AT/RT</strong>. Key clues: infant <1yr, subcapsular fluid collection (characteristic of MRTK), synchronous brain mass (AT/RT in 25%). SMARCB1/INI1 loss confirmed in both." }
    };

    function checkAnswer(el, isCorrect, quizId) {
      if (answered[quizId]) return;
      answered[quizId] = true;
      totalAnswered++;
      const options = el.parentElement.querySelectorAll('.quiz-option');
      options.forEach(opt => opt.style.pointerEvents = 'none');
      const feedback = document.getElementById(quizId + '-feedback');
      if (isCorrect) {
        score++;
        el.classList.add('correct');
        feedback.className = 'quiz-feedback show correct-fb';
        feedback.innerHTML = '<i class="fas fa-check-circle"></i> ' + explanations[quizId].correct;
      } else {
        el.classList.add('incorrect');
        options.forEach(opt => { if (opt.onclick && opt.onclick.toString().includes('true')) opt.classList.add('correct'); });
        feedback.className = 'quiz-feedback show incorrect-fb';
        feedback.innerHTML = '<i class="fas fa-times-circle"></i> ' + explanations[quizId].incorrect;
      }
      document.getElementById('quiz-score').textContent = score;
      document.getElementById('quiz-total').textContent = totalAnswered;
      document.getElementById('score-tracker').style.display = 'block';
      document.getElementById('final-correct').textContent = score;
      const pct = (score / totalQuestions) * 100;
      document.getElementById('final-bar-fill').style.width = pct + '%';
      if (totalAnswered === totalQuestions) {
        let msg = pct >= 90 ? 'Outstanding! You have mastered pediatric renal masses!' : pct >= 70 ? 'Great job! Review the topics you missed.' : pct >= 50 ? 'Good effort! Review the key sections again.' : 'Keep studying! Use this presentation as a reference.';
        document.getElementById('final-message').textContent = msg;
      }
    }
  </script>
</body>
</html>
